Clinical Research
Using Novel Technology for Developing New Ways to Deliver and Experience New Medicines
Overview
Our Pharmaceutical Medicines
CURE is conducting clinical research on a variety of active pharmaceutical ingredients (APIs), both internally and through partnerships, mostly utilizing our proprietary drug delivery platform CUREfilm®. The focus of our programs is addressing novel approaches to meaningful disease states that are either undercovered or underappreciated by larger pharmaceutical players. These areas have high barriers to entry and benefit from drug delivery expertise. Our strategy is to capture these opportunities wherever possible using the 505(b)2 regulatory pathway, which enables us to seek regulatory approval at a faster pace than other pathways.
STRATEGIC
Approach
- PRODUCT DEVELOPMENT/DRUG DELIVERY EXPERTISE
- PROPRIETARY PLATFORM TECHNOLOGY
- STRATEGIC FOCUS ON LIKELIHOOD OF SUCCESS
- ABBREVIATED REGULATORY PATHWAY – 505(b)2
- DIFFERENTIATED DOSAGE FORMS/ROUTE OF ADMIN.
- MARKET/COMMERCIALIZATION
CURE PHARMACEUTICAL
Clinical Pipeline
Formulation Development
Clinical Development
Regulatory Filing
Launch
- CUREfilm® Blue (Sildenafil Citrate) 77%
- CUREfilm® Anti-Viral 52%
- CUREfilm® Mental Health Disorders (Multiple Psychedelic Compounds) 42%
- CUREfilm® Central Nervous System Disorders 42%
- CUREfilm® Canna (THC+CBD) FOR EXTERNAL PARTNERING 52%
FOR LICENSING OPPORTUNITIES AND INDUSTRY PARTNERSHIPS
Call 516.660.9148 or email us below:
PHARMACEUTICAL
Focus Areas

Focus Area
Novel Delivery of Known APIs









Focus Area
Unmet Need Applications



Focus Area
Scheduled Compounds



CUREfilm® products
Optimized Delivery
Active ingredients in the CUREfilm® dose form can be either pre-solubilized within its matrix or encapsulated, or both for more effective absorption and/or sustained release. As oral thin films quickly dissolve, no water is required for their administration, improving patient compliance – especially among the elderly, children, and in conditions where patients have difficulty in swallowing.
Novel Delivery of APIs


Specific release profiles


Increased bioavailability


Better patient experience


Protection from degradation
enhancing stability and extending shelf life.
Our Pharmaceutical Drug Development Using Novel Delivery
CUREfilm Blue
CUREfilm® Explained


Unmet Need Applications
PROGRAM ADVANTAGES


Central Nervous System (CNS) Disease States
Our Pharmaceutical Medicines
CUREfilm® Anti-Viral
CUREfilm® for Central Nervous System Disorders
CUREfilm® Cannabis
CUREfilm® Blue
CUREfilm® Entheogenic Compounds
Proprietary Pharmaceutical Drug Development Programs Seeking Industry Partnership Opportunities
Pursuing University Collaborations to Support Clinical Research for High Unmet Need Disease States
Targeting FDA Submission and Approval with Alliances toward Commercial Success
researching
Scheduled Compounds
ENDOCANNABINOID SYSTEM RESEARCH
Cannabinoid research presents a unique opportunity for CURE, having successfully proved that our novel delivery system CUREfilm® improves the bioavailability of cannabinoids in the body. Many large pharmaceutical companies are researching the potential therapeutic benefits of cannabinoids such as Tetrahydrocannabinol (THC) and cannabidiol (CBD). CURE is conducting on-going clinical research on cannabinoids, both internally and through partnerships.
Cancer Research Collaboration with Technion-Israel Institute of Technology
Researchers from CURE’s Pharmaceutical Cannabinoid Division and Technion’s Laboratory of Cancer Biology and Cannabinoid Research are working together to research and identify how varying cannabinoid compounds within cannabis strains can affect various cancer subtypes. The results of the research will be used to predict how to match a cancer subtype with an effective cannabis extract in order to optimize treatment efficacy.

